Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking

This study examined the association of post‐treatment changes in cognitive performance, apolipoprotein E (APOE), and smoking in breast cancer patients treated with adjuvant therapy.

[1]  Andrew J Saykin,et al.  Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Leon Bieber,et al.  Sas System For Mixed Models , 2016 .

[3]  M. D’Esposito,et al.  Estrogen Shapes Dopamine-Dependent Cognitive Processes: Implications for Women's Health , 2011, The Journal of Neuroscience.

[4]  C. Gundy,et al.  Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Slotkin.  Nicotine and the adolescent brain: insights from an animal model. , 2002, Neurotoxicology and teratology.

[6]  Susan Bookheimer,et al.  APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. , 2009, Annual review of clinical psychology.

[7]  G. Schellenberg,et al.  The Effect of Apolipoprotein E ε4 in the Relationships of Smoking and Drinking to Cognitive Function , 1999, Neuroepidemiology.

[8]  H. Jim,et al.  Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Robin J. Prescott,et al.  Applied Mixed Models in Medicine: Brown/Applied Mixed Models in Medicine, 2nd Edition , 2006 .

[10]  R. Mayeux,et al.  Effect of smoking and time on cognitive function in the elderly without dementia , 2005, Neurology.

[11]  J. Kastelein,et al.  Apolipoprotein E genotyping on agarose gels. , 1995, Clinical chemistry.

[12]  T. Ahles,et al.  International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. , 2011, The Lancet. Oncology.

[13]  M. Kenward,et al.  Small sample inference for fixed effects from restricted maximum likelihood. , 1997, Biometrics.

[14]  T. Ahles,et al.  Brain vulnerability to chemotherapy toxicities , 2012, Psycho-oncology.

[15]  Andrew J. Saykin,et al.  Cognitive function in breast cancer patients prior to adjuvant treatment , 2008, Breast Cancer Research and Treatment.

[16]  H. Jim,et al.  Catechol‐O‐methyltransferase genotype modulates cancer treatment‐related cognitive deficits in breast cancer survivors , 2011, Cancer.

[17]  A. Saykin,et al.  The relationship of APOE genotype to neuropsychological performance in long‐term cancer survivors treated with standard dose chemotherapy , 2003, Psycho-oncology.

[18]  Andrew J. Saykin,et al.  Candidate mechanisms for chemotherapy-induced cognitive changes , 2007, Nature Reviews Cancer.

[19]  J. Baños,et al.  California Verbal Learning Test-Second Edition , 2002 .

[20]  Andrew J Saykin,et al.  Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Adrian G Barnett,et al.  Regression to the mean: what it is and how to deal with it. , 2004, International journal of epidemiology.

[22]  D. Hedeker,et al.  The television, school, and family smoking prevention and cessation project. VIII. Student outcomes and mediating variables. , 1995, Preventive medicine.

[23]  Helen Brown,et al.  Applied Mixed Models in Medicine , 2000, Technometrics.

[24]  C. Brayne,et al.  Influence of apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers. , 2000, Epidemiology.

[25]  M. Kumari,et al.  Effect of Apolipoprotein E ε4 on the association between health behaviors and cognitive function in late midlife , 2010, Molecular Neurodegeneration.

[26]  J. Buxbaum,et al.  Extensive proteomic screening identifies the obesity-related NYGGF4 protein as a novel LRP1-interactor, showing reduced expression in early Alzheimer's disease , 2010, Molecular Neurodegeneration.

[27]  Ron Dumont,et al.  Delis‐Kaplan Executive Function System , 2008 .

[28]  J. Root,et al.  Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Andrew J. Saykin,et al.  Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study , 2010, Breast Cancer Research and Treatment.

[30]  A. Hofman,et al.  Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease , 1995, BMJ.